KR880012233A - 레트로바이러스성 감염의 예방 및 치료용약제 - Google Patents

레트로바이러스성 감염의 예방 및 치료용약제 Download PDF

Info

Publication number
KR880012233A
KR880012233A KR1019880004283A KR880004283A KR880012233A KR 880012233 A KR880012233 A KR 880012233A KR 1019880004283 A KR1019880004283 A KR 1019880004283A KR 880004283 A KR880004283 A KR 880004283A KR 880012233 A KR880012233 A KR 880012233A
Authority
KR
South Korea
Prior art keywords
pharmaceutical formulation
interferon
treatment
hydrogen
compound
Prior art date
Application number
KR1019880004283A
Other languages
English (en)
Other versions
KR960014988B1 (ko
Inventor
토마스 프렌더가스트 패트릭
Original Assignee
토마스 프렌더가스트 패트릭
원본미기재
콜쓰루스트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 토마스 프렌더가스트 패트릭, 원본미기재, 콜쓰루스트 리미티드 filed Critical 토마스 프렌더가스트 패트릭
Publication of KR880012233A publication Critical patent/KR880012233A/ko
Application granted granted Critical
Publication of KR960014988B1 publication Critical patent/KR960014988B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

내용 없음

Description

레트로바이러스성 감염의 예방 및 치료용약제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 일반식(I)의 화합물을 함유함을 특징으로 하는, 레트로바이러스성 감염증, 또는 이의 합병증 또는 후속 증상의 예방 및 치료에 사용하기 위한 약제학적 제제.
    상기식에서, R은 수소 또는 브롬원자이고 ; R1은 수소원자, SO2OM 그룹(여기에서, M은 수소 또는 나트륨 원자이다), 설파티드 그룹
    또는 포스파티드 그룹
    (여기에서, R2및 R3는 각각 동일하거나 상이할 수 있으며, 탄소수 1 내지 14의 직쇄 또는 측쇄 알킬 라디칼이다)이거나, 글루쿠로나이드 그룹
    파선(---)은 임의의 이중경합을 나타내고 ; 5 위치에서의 수소원자는- 또는- 배위로 존재하거나 두배위의 혼합형으로 존재한다.
  2. 제 1항에 있어서, 일반식(I)의 화합물에서 R 및 R1이 각각 수소인 약제학적 제제.
  3. 제 2항에 있어서, 일반식(I)의 화합물에서 R 및 R1이 각각 수소이고 이중결합이 존재하는, 데하이드로 에피안드로스테론인 약제학적 제제.
  4. 제 1항에 있어서, 일반식(I)의 화합물이 R이 브롬이고, R1이 수소이며 이중결합이 존재하는, 16-브로모에피안드로스페론인 약제학적 제제.
  5. 제 1항에 있어서, 일반식(I)의 화합물이 데하이드로에피안드로스테론 설페이트인 약제학적 제제.
  6. 제 1항 내지 제 5항 중 어느 한 항에 있어서, 일반식(I)의 화합물을 전신게 투여용으로 제형화시킨 약제학적 제제.
  7. 제 1항 내지 제 6항 중 어느 한 항에 있어서, 레트로 바이러스성 감염, 또는 이의 합병증 또는 후속 증상의 예방제 및 치료제로서 면역 조절제와 동시에 또는 배합하여 사용하기 위한, 약제학적 제제.
  8. 제 7항에 있어서, 면역 조절제가 앰플리겐(Ampligen), 항-인체형-인터페론 항체, 안티-AIDS항체, 아스코르브산 및 이의 유도체, 브로피리민(Bro-pirimine) 시아멕손(Ciamexon), 사이클로스포린(Cycolsporin), 시메티딘(Cimetidine), 콜로니 자극인자, 디니트로클로로벤젠,-인터페론,-인터페론,-인터페론, 글루칸,-글로불린, 인터루킨(Interleukin) 1, 인터루켄(Interleuken) 2, 이소프리노신, 크레스틴(Krestin), 렌티난(Lentinan), 메티오닌-엔케팔린, 미노파겐(Minophagen) C, 무라밀 프리펩티드, 날트렉손(Naltrexone), 뉴트로핀(Neutropin), 폴리만노아세테이트 RNA 면역 조절제, 소사이코토(Shosaikoto) 및 인삼, 나트륨 디에틸티오카바메이트, 흉선 액소성 인자, 티모펜틴(Thymopentin), 티모신(Thymosin) 분획 5 및 티모신1, 티모스티물린, 종양 괴사인자 및 비타민 B 제제로부터 선택되는 약제학적 제제.
  9. 제 1항 내지 6항중 어느 한 항에 있어서, 레트로 바이러스성 감염, 또는 이의 합병증 또는 후속 증상의 예방 및 치료에 항바이러스제와 동시에 또는 배합하여 사용하기 위한, 약제학적 제제.
  10. 제 9항에 있어서, 항바이러스제가 앰포테리신(Amphotericin) B 메틸 에스테르, 암모늄-21-텅스토-9-안티모네이트, 앰플리겐(Ampligen), 안티-AIDS 항체, 안사마이신, 아지도티미딘 또는 이의 5-비치환된 유도체, 부틸화된 하이드록시톨루엔, 카스타노스페르민(Castano-spermine), 사이토벤(Cytovene), 디데옥시아데노신, 디데옥시사이티딘, 덱스트란 설페리트, 에플로르니틴, 포스카네트(Foscarnet), 푸시드산, 글리시리진,-인터페론,-인터페론, 논옥시놀(Nonoxinol), 펜타미딘 이세티오네이트, 펩티드(Peptide)T, 페니토인(Pheny-toin), 폴리만노아세테이트, 리바비린(Ribavirin, 재조합 가용성 T4, 트리메트렉세이트(Trimetrexate), 수라민(Suramin) 및 이들의 동족체로 부터 선택되는 약제학적 제제.
  11. 제 1항 내지 제 10항 중 어느 한 항에 있어서, HIV감염, 또는 이의 합병증 또는 후속 증상의 예방 및 치료에 사용하기 위한 약제학적 제제.
  12. 제 1항 내지 10항 중 어느 한 항에 있어서, 후천성 면역 결핍증(AIDS)의 예방 및 치료에 사용하기 위한 약제학적 제제.
  13. 제 1항 내지 10항 중 어느 한 항에 있어서, 후천성 면역 결핍증 관련 컴플렉스(ARC)의 예방 및 치료에 사용하기 위한 약제학적 제제.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019880004283A 1987-04-16 1988-04-15 레트로바이러스성 감염의 예방 및 치료용 약제 KR960014988B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IE997/87 1987-04-16
IE99787 1987-04-16
IE2289/87 1987-08-27
IE228987 1987-08-27

Publications (2)

Publication Number Publication Date
KR880012233A true KR880012233A (ko) 1988-11-26
KR960014988B1 KR960014988B1 (ko) 1996-10-23

Family

ID=26319024

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880004283A KR960014988B1 (ko) 1987-04-16 1988-04-15 레트로바이러스성 감염의 예방 및 치료용 약제

Country Status (23)

Country Link
US (1) US4956355A (ko)
JP (1) JP2577771B2 (ko)
KR (1) KR960014988B1 (ko)
AT (1) AT401470B (ko)
AU (1) AU608824B2 (ko)
BE (1) BE1004315A5 (ko)
CA (1) CA1325594C (ko)
CH (1) CH675358A5 (ko)
DE (1) DE3812595C2 (ko)
DK (1) DK175582B1 (ko)
FI (1) FI881773A (ko)
FR (1) FR2615394B1 (ko)
GB (1) GB2204237B (ko)
GR (1) GR1002240B (ko)
IL (1) IL86089A (ko)
IT (1) IT1227073B (ko)
LU (1) LU87202A1 (ko)
NL (1) NL194728C (ko)
NZ (1) NZ224272A (ko)
OA (1) OA08729A (ko)
PH (1) PH25907A (ko)
PT (1) PT87259B (ko)
SE (1) SE503482C2 (ko)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687692T2 (de) * 1985-11-13 1993-05-19 Japan Res Dev Corp Geschlechtshormone zur behandlung von immun-mangel-krankheiten.
US5356900A (en) * 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
US6638894B1 (en) * 1987-01-09 2003-10-28 Lucent Technologies Inc. Devices and systems based on novel superconducting material
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
EP0309519B1 (en) * 1987-04-09 1992-07-08 FISONS plc Pharmaceutical compositions containing pentamidine
US5407684A (en) * 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5077284A (en) * 1988-12-30 1991-12-31 Loria Roger M Use of dehydroepiandrosterone to improve immune response
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
CA2066716A1 (en) * 1989-09-25 1991-03-26 Raymond A. Daynes Use of steroid hormones in compositions for inducing t cell lymphokine production
US5824313A (en) * 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5753237A (en) * 1989-09-25 1998-05-19 University Of Utah Research Foundation Method for augmenting immunological responses
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
IE63418B1 (en) * 1990-09-10 1995-04-19 Elan Corp Plc Progression risk of HIV by assay of dehydroepiandrosterone in body fluid
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
JPH05317041A (ja) * 1991-06-05 1993-12-03 Nippon Oil Co Ltd 動物細胞増殖促進剤及び無血清培地
US5230897A (en) * 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
EP0627921B1 (en) * 1992-02-24 2000-05-31 East Carolina University Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
JPH07506372A (ja) * 1992-05-01 1995-07-13 ユニバーシティ・オブ・ユタ インビボでのｉｌ−６産生を調節する組成物および方法
US5346997A (en) * 1992-08-26 1994-09-13 Murphy James G Agents for complexing sodium under biological conditions
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
ES2227523T3 (es) * 1993-01-19 2005-04-01 Endorecherche Inc. Usos terapeuticos y sistemas de suministro de deshidroepiandrosterona.
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5439899A (en) * 1993-03-10 1995-08-08 Purdue Research Foundation Cosalane and related compounds having activity against aids and aids-related infections
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
US5466465A (en) * 1993-12-30 1995-11-14 Harrogate Holdings, Limited Transdermal drug delivery system
ATE412769T1 (de) * 1994-04-05 2008-11-15 Morre D James Nadh-oxidase als zielmolekül in diagnose und therapie
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US7893044B2 (en) * 1995-02-24 2011-02-22 Epigenesis Pharmaceutical, Inc. Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrosterone
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US6162450A (en) * 1995-05-15 2000-12-19 Avon Products, Inc. Uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same
CA2244535A1 (en) * 1995-05-15 2000-01-30 Avon Products, Inc. Novel uses for ascorbyl-phosphoryl-cholesterol in topical compositions
US5736537A (en) * 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
DE69605556T2 (de) * 1996-05-14 2000-06-15 Avon Prod Inc Ascorbyl-phosphorylcholesterol
GB9612990D0 (en) * 1996-06-20 1996-08-21 Stanford Rock Ltd Compositions and methods for the treatment of chronic infections
US5885977A (en) * 1997-01-15 1999-03-23 Humanetics Corporation Use of Δ5 androstenes in the treatment of HIV wasting syndrome
US5902593A (en) * 1997-10-01 1999-05-11 Kent; Frances B. Topically applied personal lubricant containing benzalkonium chloride as the active ingredient
CA2352205A1 (en) * 1998-11-24 2000-06-08 Hollis-Eden Pharmaceuticals, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other togaviruses
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
CA2356539A1 (en) * 1998-11-24 2000-06-08 Hollis-Eden Pharmaceuticals, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of african and american trypanosomiasis
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
AP2001002167A0 (en) * 1998-11-27 2001-06-30 Hollis Eden Pharmaceuticals Use of 17-ketosteroids for the treatment of toxoplasmosis and crytosporidiosis
NZ513803A (en) * 1999-03-23 2004-06-25 Hollis Eden Pharmaceuticals Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
EP1422234A3 (en) * 1999-03-23 2010-12-08 Harbor BioSciences, Inc. Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
FR2792201B1 (fr) * 1999-04-15 2001-11-02 Donatien Mavoungou Procede du renforcement immunitaire et du developpement d'un transporteur lipidique pour une therapie genique anti-vih et anti-bacterienne
US20050245502A1 (en) * 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US7479498B2 (en) * 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
DK1955700T3 (da) 1999-09-30 2011-05-23 Harbor Biosciences Inc Terapeutisk behandling af androgenreceptor-betingede lidelser
US20050070487A1 (en) * 2001-04-24 2005-03-31 Nyce Jonathan W. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
MXPA04012728A (es) * 2002-06-17 2006-02-02 Epigenesis Pharmaceuticals Llc Deshidroepiandrosterona dihidratada y metodos para el tratamiento de asma o una enfermedad pulmonar obstructiva cronica utilizando composiciones de la misma.
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005200A (en) * 1975-07-17 1977-01-25 Kanebo, Ltd. Method for improving the maturity of the parturient canal and the sensitivity to oxytocin
SE439586B (sv) * 1975-09-05 1985-06-24 Kanebo Ltd Sett att framstella ett stabilt farmaceutiskt torrpreparat av ett alkalimetallsalt av dehydroepiandrosteronsulfat
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
EP0133995B1 (en) * 1983-08-02 1992-04-15 Research Corporation Technologies, Inc. Steroids and therapeutic compositions containing same
US4507289A (en) * 1983-12-28 1985-03-26 Progenics, Inc. Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen
US4602008A (en) * 1984-12-14 1986-07-22 Progenics, Inc. Alkylated etiocholanolones and use as an anti-diabetic, anti-obesity and erythropoietic agent
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
NL8502571A (nl) * 1985-09-20 1987-04-16 Akzo Nv Steroiden met immunomodulerende eigenschappen.
DE3687692T2 (de) * 1985-11-13 1993-05-19 Japan Res Dev Corp Geschlechtshormone zur behandlung von immun-mangel-krankheiten.

Also Published As

Publication number Publication date
SE8801406D0 (sv) 1988-04-15
FI881773A0 (fi) 1988-04-15
DE3812595C2 (de) 1997-07-03
NL8800926A (nl) 1988-11-16
DK208188D0 (da) 1988-04-15
IT8847858A0 (it) 1988-04-15
FI881773A (fi) 1988-10-17
GB2204237A (en) 1988-11-09
FR2615394A1 (fr) 1988-11-25
GR1002240B (en) 1996-04-22
IT1227073B (it) 1991-03-14
US4956355A (en) 1990-09-11
AU1467888A (en) 1988-10-20
SE503482C2 (sv) 1996-06-24
GB2204237B (en) 1991-02-06
AT401470B (de) 1996-09-25
IL86089A (en) 1992-11-15
LU87202A1 (fr) 1988-11-17
NL194728B (nl) 2002-09-02
PH25907A (en) 1991-12-19
GR880100248A (el) 1989-01-31
DK208188A (da) 1988-10-17
DK175582B1 (da) 2004-12-13
DE3812595A1 (de) 1988-10-27
PT87259B (pt) 1992-08-31
KR960014988B1 (ko) 1996-10-23
SE8801406L (sv) 1988-10-17
NL194728C (nl) 2003-01-07
IL86089A0 (en) 1988-09-30
CA1325594C (en) 1993-12-28
FR2615394B1 (fr) 1994-09-23
BE1004315A5 (fr) 1992-11-03
JP2577771B2 (ja) 1997-02-05
NZ224272A (en) 1991-09-25
PT87259A (pt) 1988-05-01
AU608824B2 (en) 1991-04-18
JPS6425722A (en) 1989-01-27
CH675358A5 (ko) 1990-09-28
OA08729A (en) 1989-03-31
ATA98488A (de) 1996-02-15
GB8808864D0 (en) 1988-05-18

Similar Documents

Publication Publication Date Title
KR880012233A (ko) 레트로바이러스성 감염의 예방 및 치료용약제
DE69633398T2 (de) Betulinsäure-derivate und ihre verwendungen
DE69934486T2 (de) Acylierte betulin- und dihydrobetulinderivate, ihre herstellung und verwendung
EP0196268B1 (de) Estriolester
US7365221B2 (en) Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20030153538A1 (en) Antitumor agent
WO2005090380A1 (en) Pharmaceuticals salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
WO1987005294A1 (en) Cyclodextrinclathrates of carbacycline derivatives and their use as medicinal drugs
EP0198829B1 (de) 9-halogen-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0069696A2 (de) 9-Fluor-prostaglandinderivate, Verfahren zur Herstellung und Verwendung als Arzneimittel
CA2194049A1 (en) Novel clinical uses of polyene macrolides
KR920017659A (ko) 면역 이상작용과 관련된 변성 병변에서 포스파티딜세린 및 이의 유도체의 용도
US20040131629A1 (en) Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050148561A1 (en) Novel triterpene derivatives, preparation thereof and use thereof
KAMANO et al. Rhinovirus inhibition by bufadienolides
EP0312222B1 (en) Treatment of diseases caused by viruses
AT396687B (de) Cyclodextrinclathrate von 5-cyanoprostacyclinderivaten und ihre verwendung als arzneimittel
EP0260057A3 (en) 2-oxo-4-carboxy-pyrimidines
Howe et al. Effect of dietary bile acids on plasma cholesterol of the rat
AU605127B2 (en) Carbacyclins
ZA200602758B (en) Novel triterpene derivatives, preparation thereof and use thereof
JPH064563B2 (ja) トリテルペン化合物及び制癌剤
JPS6045524A (ja) 抗炎症剤
JPH02286619A (ja) 利胆剤
MXPA06003252A (en) Novel triterpene derivatives, preparation thereof and use thereof

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20051018

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee